F
Frédéric Baribaud
Researcher at Janssen Pharmaceutica
Publications - 81
Citations - 6929
Frédéric Baribaud is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: DC-SIGN & Virus. The author has an hindex of 39, co-authored 74 publications receiving 6260 citations. Previous affiliations of Frédéric Baribaud include Incyte & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Nathan R. West,Ahmed N. Hegazy,Owens Bmj.,Samuel J. Bullers,Bryan Linggi,Sofia Buonocore,Margherita Coccia,Dieter Görtz,S This,K Stockenhuber,Johanna Pott,Matthias Friedrich,Grigory Ryzhakov,Frédéric Baribaud,Carrie Brodmerkel,C Cieluch,Nahid Rahman,Gerhard Müller-Newen,Raymond J. Owens,Raymond J. Owens,Anja A. Kühl,Kevin J. Maloy,S Plevy,Satish Keshav,Travis Spl.,Fiona Powrie +25 more
TL;DR: It is shown that, relative to healthy controls, inflamed intestinal tissues from patients with IBD express high amounts of the cytokine oncostatin M (OSM) and its receptor (OSMR), which correlate closely with histopathological disease severity.
Journal ArticleDOI
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
Stefan Pöhlmann,Jie Zhang,Frédéric Baribaud,Zhiwei Chen,George J. Leslie,George Lin,Angela Granelli-Piperno,Robert W. Doms,Charles M. Rice,Jane A. McKeating +9 more
TL;DR: It is found that soluble versions of the hepatitis C virus (HCV) E2 glycoprotein and retrovirus pseudotypes expressing chimeric forms of both HCV E1 and E1 glycoproteins bound efficiently toDC-SIGN and DC-SIGNR expressed on cell lines and primary human endothelial cells but not to other C-type lectins tested.
Journal ArticleDOI
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou,Michael Peyton,Biao He,Changnian Liu,Luc Girard,Eian Caudler,Yvonne Lo,Frédéric Baribaud,Iwao Mikami,Noemi Reguart,Gengjie Yang,Yanlong Li,Wenqing Yao,Kris Vaddi,Adi F. Gazdar,Steven Friedman,David M. Jablons,Robert C. Newton,Jordan S. Fridman,John D. Minna,Peggy Scherle +20 more
TL;DR: The results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.
Journal ArticleDOI
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.
Graham Simmons,Jacqueline D. Reeves,Case C. Grogan,Luk H. Vandenberghe,Frédéric Baribaud,J. Charles Whitbeck,Emily Burke,Michael J. Buchmeier,Elizabeth J. Soilleux,James L. Riley,Robert W. Doms,Paul Bates,Stefan Pöhlmann +12 more
TL;DR: It is demonstrated that the C-type lectins DC-SIGN and DC-signR avidly bind Ebola glycoproteins and greatly enhance transduction of primary cells by Ebola virus pseudotypes and infection by replication-competent Ebola virus.
Journal ArticleDOI
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Ingrid Arijs,Katherine Li,G. Toedter,Roel Quintens,L. Van Lommel,K. Van Steen,Peter Leemans,G. De Hertogh,Katleen Lemaire,Marc Ferrante,F. Schnitzler,Lieven Thorrez,K. Ma,X.-Y. R. Song,Colleen Marano,G. Van Assche,Severine Vermeire,K. Geboes,Frans Schuit,Frédéric Baribaud,Paul Rutgeerts +20 more
TL;DR: Gene array studies of ulcerative colitis mucosal biopsies identified predictive panels of genes for (non-response) response to infliximab, and further study of the pathways involved should allow a better understanding of the mechanisms of resistance to inflIXimab therapy in ulceratives colitis.